文献速递湿疹皮炎与荨麻疹

口服阿布昔替尼对中重度特应性皮炎青少年患者报告结局的影响:体征、症状与生活质量分析

Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2021-12-04

本文基于三项3期随机双盲安慰剂对照研究(JADE TEEN、JADE MONO-1、JADE MONO-2),评估口服阿布昔替尼(200或100 mg,每日一次)治疗12周对12-17岁中重度特应性皮炎青少年患者报告体征/症状、睡眠损失及生活质量的影响。结果显示,与安慰剂相比,阿布昔替尼单药或联合外用治疗均显著改善患者报告结局。

要点

  • 第12周时,阿布昔替尼200 mg和100 mg组达到POEM较基线改善≥4分的比例均高于安慰剂组。
  • 第12周时,阿布昔替尼200 mg和100 mg组达到CDLQI较基线改善≥6分的比例均高于安慰剂组。
  • 第2-12周,阿布昔替尼组SCORAD视觉模拟量表睡眠损失评分较安慰剂组显著改善。

核心结论

  • 在伴有中重度特应性皮炎的青少年中,阿布昔替尼单药或联合外用治疗较安慰剂显著改善患者报告的体征/症状,包括减少睡眠损失和改善生活质量。

研究设计与样本

  • 三项3期随机双盲安慰剂对照研究(JADE TEEN、JADE MONO-1、JADE MONO-2)在亚太地区、欧洲和北美开展。
  • 纳入12-17岁中重度特应性皮炎患者,且对连续≥4周外用药物或系统治疗应答不充分。
  • 患者随机接受每日一次口服阿布昔替尼(200或100 mg)或安慰剂治疗12周;JADE TEEN为联合外用治疗,JADE MONO-1/-2为单药治疗。
  • JADE TEEN随机比例1:1:1,JADE MONO-1/-2随机比例2:2:1;JADE MONO-1/-2的青少年患者数据被汇总分析。

主要发现

  • 第12周时,JADE TEEN中阿布昔替尼200 mg组83.9%、100 mg组77.0% vs 安慰剂组60.2%达到POEM较基线改善≥4分。
  • 第12周时,JADE MONO-1/-2中阿布昔替尼200 mg组83.0%、100 mg组69.4% vs 安慰剂组43.5%达到POEM较基线改善≥4分。
  • 第12周时,JADE TEEN中阿布昔替尼200 mg组73.8%、100 mg组67.5% vs 安慰剂组56.5%达到CDLQI较基线改善≥6分。
  • 第12周时,JADE MONO-1/-2中阿布昔替尼200 mg组70.0%、100 mg组57.1% vs 安慰剂组19.0%达到CDLQI较基线改善≥6分。
  • JADE TEEN和JADE MONO-1/-2中,第2-12周阿布昔替尼组SCORAD视觉模拟量表睡眠损失评分较安慰剂组显著改善。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A significant improvement in clinical signs was demonstrated with abrocitinib relative to placebo in adolescents with moderate-to-severe atopic dermatitis (AD) in three phase 3, randomized, double-blinded, placebo-controlled studies (JADE TEEN [ClinicalTrials.gov, NCT03796676], JADE MONO-1 [NCT03349060] and JADE MONO-2 [NCT03575871]). OBJECTIVES: To evaluate the impact of abrocitinib on patient-reported signs/symptoms, including sleep loss and quality of life among adolescents with moderate-to-severe AD. METHODS: JADE TEEN, JADE MONO-1 and JADE MONO-2 were conducted in the Asia-Pacific region, Europe and North America and included patients aged 12-17 years with moderate-to-severe AD and inadequate response to ≥ 4 consecutive weeks of topical medication or treatment with systemic therapy for AD. Patients were randomly assigned (1 : 1 : 1, JADE TEEN; 2 : 2 : 1, JADE MONO-1/-2) to receive once-daily oral abrocitinib (200 or 100 mg) or placebo for 12 weeks in combination with topical therapy (JADE TEEN) or as monotherapy (JADE MONO-1/-2). Data from adolescent patients in JADE MONO-1/-2 were pooled for these analyses. RESULTS: At week 12, more adolescents treated with abrocitinib (200 or 100 mg) vs. placebo achieved a ≥ 4-point improvement from baseline in the Patient-Oriented Eczema Measure in JADE TEEN (83.9% and 77.0% vs. 60.2%) and JADE MONO-1/-2 (83.0% and 69.4% vs. 43.5%) and a ≥ 6-point improvement from baseline in the Children's Dermatology Life Quality Index in JADE TEEN (73.8% and 67.5% vs. 56.5%) and JADE MONO-1/-2 (70.0% and 57.1% vs. 19.0%). Significant improvements in SCORing Atopic Dermatitis Visual Analog Scale for sleep loss scores were demonstrated with abrocitinib vs. placebo at weeks 2-12 in JADE TEEN and JADE MONO-1/-2. CONCLUSIONS: Patient-reported signs/symptoms, including reduction of sleep loss and quality of life, were substantially improved with abrocitinib monotherapy or combination therapy relative to placebo in adolescents with moderate-to-severe AD.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Cork MJ, McMichael A, Teng J, et al. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes. J Eur Acad Dermatol Venereol. 2021. PMID: 34743361. doi:10.1111/jdv.17792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。